The use of the SiMoA technology to prove PD-L1 presence on EVs may also be a viable approach to predict tumor PD-L1 expression levels, and potentially stratify responders and nonresponders of immune checkpoint inhibitor therapy in a noninvasive manner (132). The gene discussed is CD274; the disease is neoplasm.